VTRS · Viatris Inc
Market Cap
$18.77B
Shares
1.15B
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$14.3B
-3%
FY2025
Net Income
-$3.51B
-454.2%
FY2025
Gross Margin
35.06%
-3.1pp
FY2025
Operating Margin
-18.62%
-18.7pp
FY2025
Diluted EPS
-$3.00
-466%
FY2025
Operating Cash Flow
$2.32B
+0.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $14.74B | $14.3B | $14.74BG | $15.43B | $16.26B | $17.89B | $11.95B | $11.5B | $11.43B | |
| $9.6B | $9.29B | $9.12B | $8.99B | $9.77B | $12.31B | $8.15B | $7.6B | $7.43B | |
| $5.13B | $5.01B | $5.62B | $6.44B | $6.5B | $5.58B | $3.8B | $3.9B | $4B | |
| — | 35.06% | 38.15% | 41.74% | 39.95% | 31.17% | 31.78% | 33.89% | 35% | |
| $1.02B | $965.9M | $808.7M | $805.2M | $662.2M | $751.1M | $555.1M | $639.9M | $704.5M | |
| $3.98B | $3.79B | $4.1B | $4.07B | $4.18B | $4.53B | $3.34B | $2.56B | $2.44B | |
| $2.35B | $2.35B | $2.35B | $2.32B | $2.5B | $2.7B | $1.61B | $1.58B | $1.61B | |
| $2.8B | $2.8B | $2.89B | $2.74B | $3.03B | $4.51B | $2.22B | $2.02B | $2.11B | |
| — | — | — | — | — | $50.5M | $50.5M | $104.6M | — | |
| $5.22B | $7.68B | $5.61B | $5.67B | $4.88B | $5.61B | $4.01B | $3.18B | $3.1B | |
| -$87.3M | -$2.66B | $10.1M | $766.2M | $1.61B | -$34M | -$210.8M | $715.5M | $905.6M | |
| — | -18.62% | 0.07% | 4.97% | 9.93% | -0.19% | -1.76% | 6.22% | 7.92% | |
| $2.72B | $135.2M | $2.9B | $3.51B | $4.64B | $4.47B | $2.01B | $2.73B | $3.02B | |
| $480M | $471.3M | $550M | $573.1M | $592.4M | $636.2M | $497.8M | $517.3M | $542.3M | |
| -$94.9M | -$530.6M | -$83.3M | $9.8M | $1.79B | $5.8M | -$12.6M | -$43.8M | -$64.9M | |
| — | — | — | $0 | $0 | -$61.9M | -$48.4M | -$62.1M | -$78.7M | |
| -$662.2M | -$3.67B | -$623.2M | $202.9M | $2.81B | -$664.4M | -$721.2M | $154.4M | $298.4M | |
| -$251.5M | -$150.1M | $11M | $148.2M | $734.6M | $604.7M | -$51.3M | $137.6M | -$54.1M | |
| — | -$3.51B | -$634.2M | $54.7M | $2.08B | -$1.27B | -$669.9M | $16.8M | $352.5M | |
| — | -24.58% | -4.3% | 0.35% | 12.78% | -7.1% | -5.61% | 0.15% | 3.08% | |
| USD/shares | -$0.40 | -$3.00 | -$0.53 | $0.05 | $1.71 | -$1.05 | -$1.11 | $0.03 | $0.69 |
| USD/shares | -$0.40 | -$3.00 | -$0.53 | $0.05 | $1.71 | -$1.05 | -$1.11 | $0.03 | $0.68 |
| shares | — | — | — | 1.2B | 1.21B | 1.21B | 601.2M | 515.7M | 514.5M |
| shares | — | — | — | 1.21B | 1.22B | 1.21B | 601.2M | 516.5M | 516.5M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2025: $1.43B in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 3.07×
EV/EBIT
—
Peer median 21.68×
P/E (TTM)
—
Peer median 23.34×
Peer medians compare against the 21 similar-size Drug Manufacturers - Specialty & Generic companies (of 97 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | $8,552,100,000 | $8,961,400,000 | $9,278,000,000 | $9,790,700,000 | $10,428,700,000 | $8,510,900,000 | $8,240,000,000 | $8,289,100,000 |
| Greater China Segment | $2,332,500,000 | $2,167,800,000 | $2,160,400,000 | $2,201,200,000 | $2,212,800,000 | $259,900,000 | $214,600,000 | $168,100,000 |
| Emerging Markets Segment | $2,217,600,000 | $2,260,400,000 | $2,562,900,000 | $2,637,000,000 | $3,144,700,000 | $1,853,800,000 | $1,723,200,000 | $1,678,700,000 |
| Japan Australia and New Zealand Segment | $1,197,700,000 | $1,349,700,000 | $1,425,600,000 | $1,633,800,000 | $2,027,400,000 | $1,195,300,000 | $1,192,500,000 | $1,132,800,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $3,006,700,000 | $3,434,700,000 | $3,551,800,000 | $3,946,600,000 | $4,176,400,000 | $3,746,100,000 | $3,965,900,000 | $3,865,200,000 |
| China | $2,079,800,000 | $1,911,300,000 | $1,889,000,000 | $1,951,300,000 | $1,981,500,000 | $216,100,000 | $171,100,000 | — |
| France | — | — | — | — | — | $1,070,800,000 | $1,047,600,000 | $1,092,700,000 |
| India | — | — | — | — | — | $1,155,400,000 | $1,171,100,000 | $1,164,800,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Brands | $9,184,000,000 | $9,200,300,000 | $9,800,500,000 | $9,889,600,000 | $10,841,300,000 | $5,234,900,000 | $5,362,100,000 | $5,523,700,000 |
| Generics | $5,066,400,000 | $5,492,500,000 | $5,587,900,000 | $6,328,500,000 | $6,972,300,000 | $5,289,500,000 | $4,796,900,000 | $5,222,400,000 |
| Lipitor | $1,549,300,000 | $1,468,800,000 | $1,559,300,000 | $1,635,200,000 | $1,663,200,000 | — | — | — |
| Norvasc | $709,900,000 | $673,300,000 | $732,400,000 | $775,100,000 | $824,700,000 | — | — | — |
| Lyrica | $487,000,000 | $495,400,000 | $556,500,000 | $623,800,000 | $728,500,000 | — | — | — |
| EpiPen Auto Injectors | $469,700,000 | $392,000,000 | $442,200,000 | $378,000,000 | $391,700,000 | — | — | — |
| Viagra | $408,200,000 | $395,600,000 | $428,800,000 | $458,900,000 | $533,800,000 | — | — | — |
| Creon | $365,800,000 | $328,200,000 | $304,900,000 | $304,000,000 | $309,800,000 | — | — | — |
| Celebrex | $272,900,000 | $285,600,000 | $330,600,000 | $338,100,000 | $344,400,000 | — | — | — |
| Yupelri | $266,900,000 | $238,500,000 | $220,800,000 | $202,100,000 | $161,900,000 | — | — | — |
| Effexor | $257,700,000 | $252,900,000 | $262,900,000 | $279,600,000 | $316,800,000 | — | — | — |
| Zoloft | $254,900,000 | $235,700,000 | $235,700,000 | $246,200,000 | $284,300,000 | — | — | — |
| Influvac | $194,400,000 | $178,700,000 | $192,400,000 | $225,500,000 | $299,300,000 | — | — | — |
| Dymista | $163,600,000 | $188,000,000 | $200,000,000 | $179,800,000 | $168,000,000 | — | — | — |
| Xalabrands | $158,400,000 | $166,400,000 | $193,200,000 | $195,100,000 | $226,000,000 | — | — | — |
| Amitiza | $158,100,000 | $149,200,000 | $157,000,000 | $167,900,000 | $201,500,000 | — | — | — |
| Xanax | $139,900,000 | $145,000,000 | $154,800,000 | $156,500,000 | $185,900,000 | — | — | — |
| Product And Service Other | — | — | — | — | — | $126,100,000 | $130,200,000 | $165,200,000 |
| Product | — | — | $15,388,400,000 | $16,218,100,000 | $17,813,600,000 | $11,819,900,000 | $11,370,300,000 | — |
| Complex GX and Biosimilars | — | — | — | $1,313,400,000 | $1,342,100,000 | $1,295,500,000 | $1,211,300,000 | $522,600,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Developed Markets Segment | $4,086,500,000 | $4,878,100,000 | $5,143,100,000 | $4,243,900,000 | $4,137,300,000 | $4,270,100,000 |
| Greater China Segment | $1,426,800,000 | $1,512,500,000 | $1,397,100,000 | $52,700,000 | $89,900,000 | $71,900,000 |
| Emerging Markets Segment | $1,091,900,000 | $1,207,100,000 | $1,402,400,000 | $610,400,000 | $561,900,000 | $647,400,000 |
| Japan Australia and New Zealand Segment | $522,900,000 | $665,500,000 | $762,400,000 | $364,600,000 | $323,200,000 | $363,100,000 |
Operating Margin by Segment (%)
| Component | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|
| Developed Markets Segment | 44% | 49.8% | 49.3% | 49.9% | 50.2% | 51.5% |
| Greater China Segment | 66% | 68.7% | 63.1% | 20.3% | 41.9% | 42.8% |
| Emerging Markets Segment | 42.6% | 45.8% | 44.6% | 32.9% | 32.6% | 38.6% |
| Japan Australia and New Zealand Segment | 36.7% | 40.7% | 37.6% | 30.5% | 27.1% | 32.1% |
Key facts
CIK
1792044
CUSIP
92556V106
13F (30d)
683 filings
624 filers
Visit website
Investor relations